Amgen Names Michael Kelly as Chief Accounting Officer

Amgen (NASDAQ:AMGN), a leading human therapeuticscompany in the biotechnology industry, today announced the appointmentof Michael Kelly as vice president, Corporate Planning and Control,and chief accounting officer. Kelly, formerly vice president, Financefor Process Development, Operations and Quality at Amgen, will reportto Richard Nanula, executive vice president and chief financialofficer. Kelly replaces Timothy Martin as Amgen's chief accountingofficer. Martin is taking on new responsibilities as Amgen's vicepresident, Finance for Global Commercial Operations.

Kelly joined Amgen in early 2003 as vice president, Finance. From2000 to 2002, Mr. Kelly was vice president, Finance and chieffinancial officer at Tanox, Inc., and from 1998 to 2000, he served ascorporate controller at Biogen, Inc. From 1981 to 1998, Mr. Kellyprogressed through positions of increasing responsibility in financeat Monsanto Life Sciences Company and its subsidiaries ending histenure as vice president, Finance with the Nutrition and Consumersector.

Kelly earned a B.S. in Business Administration from Florida A&MUniversity.

About Amgen

Amgen discovers, develops and delivers innovative humantherapeutics. A biotechnology pioneer since 1980, Amgen was one of thefirst companies to realize the new science's promise by bringing safeand effective medicines from lab, to manufacturing plant, to patient.Amgen therapeutics have changed the practice of medicine, helpingmillions of people around the world in the fight against cancer,kidney disease, rheumatoid arthritis, and other serious illnesses.With a broad and deep pipeline of potential new medicines, Amgenremains committed to advancing science to dramatically improvepeople's lives. To learn more about our pioneering science and ourvital medicines, visit www.amgen.com.